BMS-345541

BMS-345541, developed by Merck KGaA, is an anti-inflammatory, cell-permeable quinoxaline compound.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

BMS-345541, developed by Merck KGaA, is an anti-inflammatory, cell-permeable quinoxaline compound. It is an allosteric site-binding inhibitor with a primary target of IKK-2 and blocks the NF-κB-dependent transcription in mice. It has no approvals for human/medical use or for use in clinical trials. No clinical trials mention it.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1286499933 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.